Kornimate/medical-research-clean huggingface dataset:
intervention program to address ptsd in people living with hiv

Conditions: HIV; AIDS; Mindfulness-based Stress Reduction; China; Resilience; PTSD

Summary: the goal of this randomised controlled trial is to evaluate the efficacy of an integrated intervention program on post-traumatic stress disorder (ptsd) symptoms and related physiological and psychological indicators of people living with hiv (plwh). the main question it aims to answer are: * to evaluate the efficacy of the intervention program on ptsd symptoms and related physiological and psychological indicators of plwh through empirical research. * to analyze the mechanism of the intervention. eligible plwh were recruited and randomly divided as intervention group and control group. the efficacy of trauma resiliency mindfulness-informed intervention on ptsd symptoms and related physiological and psychological indicators in plwh was evaluated at baseline, after intervention, and 3 months after intervention through this randomized controlled trial. researchers compared the intervention group and control group to see if it was feasible and had potential clinical value to introduce the trauma resiliency mindfulness-informed intervention program into the management of plwh in china.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * been diagnosed with hiv for more than 1 month * screened positive with ptsd checklist - civilian version (pcl-c) * voluntary participation exclusion criteria: * impaired verbal communication * have received psychological treatment or related psychological intervention in the past three months
galectin-3 level in ankylosing spondylitis patients

Conditions: Ankylosing Spondylitis

Summary: forty-five as patients and 35 healthy controls were enrolled in this study. patients diagnosed with as according to modified new york criteria were included in the study. clinical and laboratory measurements, duration of symptoms, age and body mass index (bmi) of as patients were performed and compared with age and bmi matched control group.

detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. we excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs. we measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. the bath ankylosing spondylitis disease activity index (basdai) was used to assess disease activity in as patients.

Eligibility criteria:
inclusion criteria: * ankylosing spondylitis patients * healthy controls exclusion criteria: * hyperlipidemia * liver diseases * renal diseases * hematological diseases * familial thyroid diseases * neoplastic diseases * autoimmune infectious diseases * receiving anti-inflammatory drugs.
epid multiple sclerosis pregnancy study

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is the most common chronic neurologic disability in young adult females in their childbearing ages. little evidence is available regarding the association between exposure to ifn-beta (β) products and adverse pregnancy outcomes. therefore the four marketing holders of ifn-β are conducting a european-wide ifn-β pregnancy registry. additionally, the committee for medicinal products for human use (chmp) has requested a study to enable identification of pregnancy outcomes in the ms population unexposed to ifn-β products for comparison with the ongoing european ifn-β pregnancy registry.

information will be obtained from the drugs and pregnancy project database (dpp - fin) and the medical birth register (mbr - swe, nor). the finnish dpp and norwegian mbr include information on all stillbirths of foetuses with a birth weight of at least 500 g or with a gestational age of at least 22+0 gestational week (gw). the swedish mbr includes data on stillbirths after 28 gw the estimated number of pregnancies in ms patients needed is 1671, encompassing data from: i) fin: 1 january 1996 - 31 december 2014; ii) swe: 1 july 2005 - 31 december 2014; iii) nor: 1 january 2004 - 31 december 2014.

Eligibility criteria:
inclusion criteria: * women who have had a pregnancy with a recorded outcome consisting of an induced abortion, spontaneous abortion, ectopic pregnancy, or birth during the study period in fin, swe or nor with the event being documented in the relevant databases.
detection and automatic segmentation of liver nodules in patients with colorectal adenocarcinoma

Conditions: Detection of Liver Metastases

Summary: evaluation of the diagnostic performance of artificial intelligence-based software for the detection of liver nodules on scanner in patients at risk of liver metastases of colorectal cancer

the aim of this study is to evaluate the performance of a software for liver nodule detection in patients with colorectal cancer compared to the consensus of two radiologists analysis. 300 hepatic scanners will be analysed.

Eligibility criteria:
inclusion criteria: * patients consecutively treated for colorectal cancer a * availability of imaging by injected abdominal scanner including at least one portal phase * age over 18 exclusion criteria: * patients with treatment of the hepatic nodule by ablation or previous hepatic surgery * imaging follow-up \<12 months * non-interpretable scanner (artefact, injection quality, etc.) * patients with more than 10 liver metastases
evaluation of the truenat™mtb plus/covid-19 test for tb (tuberculosis) and covid-19 (sars-cov2)

Conditions: TB; COVID-19

Summary: this is a prospective, multicentre study in which the accuracy of the molbio diagnostics truenat™ mtb (mycobacterium tuberculosis) plus/covid-19multiplex will be assessed for tb and covid-19 case detection using prospectively collected np swabs and sputum samples from patients with symptoms suggestive of tb. the overall study period is of 24 months which includes telephonic follow-up of the baseline covid-19negative patients at 2 weeks and of all participants at 2 months.

adult patient with presumptive tb will be screened for inclusion at 4 geographically diverse participating centres in high tb burden countries. this will be the first large scale evaluation on prospectively collected fresh samples. telephonic follow-up visits at 2 weeks (for baseline covid-19 negative patients) and 2 months (for all participants) after enrolment will help overcome the challenges of using mrs only. follow-up will be conducted telephonically two weeks post-enrolment for participants who tested negative for covid-19at enrolment to determine any change in status -this is intended to account for participants who may have tested 'early' for covid-19at enrolment (false negative) but subsequently developed symptoms or tested covid-19positive. similarly, investigators will conduct a telephonic follow-up two months post-enrolment among all participants to determine if: 1) participants diagnosed with confirmed tb at enrolment were linked to treatment; and 2) assess if any new tb diagnoses were made. this multi-center study will evaluate the performance of the truenat™ mtb (mycobacterium tuberculosis) plus/covid-19multiplex test using prospectively collected np swabs and sputum samples from patients with symptoms suggestive of tb and collect alternative tongue swab samples for further research use. the data gathered from this study, will form part of the dossier to be submitted to who (world health organization) for review.

Eligibility criteria:
inclusion criteria: * adult (≥18 years); and * able to provide written informed consent in their chosen language; and * self-report at least one or more symptoms suggestive of pulmonary tb\*; and * willing to return for a day 2 visit * willing to provide oral swab samples for biobanking \* cough ≥2 weeks, fever, night sweats or unintended weight-loss exclusion criteria: * any tuberculosis preventive therapy (tpt) within 6 months prior to enrolment * any anti-tb treatment within 60 days prior to enrolment (not current episode) * unable to provide 3ml of sputum, nasopharyngeal and tongue swabs on day1 * unable to provide all study samples before starting the 3rddose of anti-tb treatment.
study to compare the diagnostic accuracy of nuance full-field digital mammography to screen-film mammography

Conditions: Breast Cancer

Summary: evaluate the diagnostic accuracy of the planmed sophie nuance full field digital mammography (ffdm) x-ray system compared to screen-film mammography (sfm) in the detection of breast cancer.

objectives: 1) to establish the non-inferiority of the diagnostic accuracy of the planmed sophie nuance full field digital mammography (ffdm) x-ray system compared to screen-film mammography (sfm) in the detection of breast cancer; and 2) to demonstrate in a comparative side-by-side feature analysis that interpretations based on the planmed sophie nuance ffdm x-ray system are diagnostically non-inferior to sfm in the detection of breast cancer.

Eligibility criteria:
inclusion criteria: 1. subject is 40 years of age or older 2. subject is presenting for routine breasts cancer screening (cohort i) or subject has one or both breasts scored 4 or 5 on the bi-rads scale as a result of sfm either for routine breast cancer screening or for follow-up or diagnostic mammography (cohort ii) 3. subject's schedule permits the sfm and the ffdm to be performed no more than 30 days apart and with no intervention between the exams 4. subject will provide prospective, written informed consent 5. subject is considered capable of complying with study procedures including a willingness to return for a one-year follow-up exam - exclusion criteria: 1. subject is pregnant or possibly pregnant or planning pregnancy within the next 15 months 2. subject has undergone a breast augmentation or breast implant? has subject had any of the following breast procedures? fine needle or cyst aspiration not eligible if within past year biopsy not eligible if within past year lumpectomy (for breast cancer) mastectomy (for breast cancer) radiation therapy breast reconstruction breast reduction not eligible if within past year 3. subject has had an invasive breast procedure or operation within the past year 4. subject has significant existing breast trauma 5. subject has a history of breast cancer treated with operation or radiation 6. subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data

Keywords: mammography
strategy of micronutrient management in parturient and layered women with a dietary supplement rich in porphyra hsp®

Conditions: Postpartum Perineal Pain

Summary: the aim of the study is to evaluate in primiparous patients the benefit of supplementation with proteochoc® to reduce perineal pain in the postpartum especially, in sitting posture. the patient is followed from the delivery to 6 to 8 weeks after.

for this study, 60 patients are going to be included. there will be 2 groups : a supplemented one (proteochoc®) and a non supplemented one (control). the patients of these two groups will have the same follow-up at the time of inclusion, an inclusion card is completed describing the patient's socio-demographic characteristics, major medical, surgical and obstetric history. after an uncomplicated delivery, women stay in maternity for a maximum of 3 days. in accordance with standard medical practice, women will be seen daily from d0 to d + 3 by the nursing staff. the investigating physician and his team will complete the follow-up sheets in the aftermath (day1), day3 and 6-8 weeks after the usual visits. the data collected are information on medication treatments, prescribed care, assessment of the patient's overall condition and recovery, and monitoring of perineal lesions and complications if applicable. in the same time (day1, day3, day6, day14 and 6-8 weeks after, the patient will also complete a patient follow-up sheet to collect her impressions. the data collected are the medications taken, the care taken, the general pain felt, the perineal pain felt if applicable, and the fatigue felt.

Eligibility criteria:
inclusion criteria: * female aged over 18 * first pregnancy * having given birth, at a term greater than or equal to 37 sa, by low route, of a single child born alive and not hospitalized in the aftermath of immediate layers * for whom the investigator has freely decided to propose a complementation by protéochoc® on the day of delivery and its sequences of layers * having freely decided to buy protéochoc® and follow the advice of consumption proposed by its gynecologist-obstetrician * having agreed to sign a consent to participate in the investigation after receiving informed information from the investigator exclusion criteria: * serious pathology running * suffering before the pregnancy of any of the following conditions: * chronic pelvic pain syndrome * ilio-inguinal, ilio-hypogastric and genito-femoral pudendal neuralgia * pains with osteo-ligamentary component: the syndrome of the dorsolumbar hinge and the coccygodynia * myofacial syndrome * pain of muscular origin: the syndrome of the pyriform muscle, syndrome of the obturator muscle * pains of venous origin: pelvic varices * allergy to any of the components of proteochoc® * patient refusing to participate or unable to participate in the survey due to major language problems or major neuropsychiatric disorders
influence of social deprivation and remoteness on quality of life in adolescent's surgical scoliosis

Conditions: Idiopathic Scoliosis

Summary: the incidence of idiopathic scoliosis is 3% or approximatively 300,000 new cases per year in france. it is estimated that between 0.1 and 0.3% of patients will eventually require surgical management, between 500 and 1000 scoliosis are operated per year in france. to our knowledge, the impact of socio-economic and territorial inequalities on the quality of life before and after surgery of idiopathic scoliosis has not been studied previously. main objective: -assess the impact of socio-economic and territorial inequalities on the pre- and post-operative quality of life at 1 year after surgical idiopathic scoliosis management, in a french pediatric surgery multicenter cohort. secondary objective: * assess the impact of socio-economic and territorial inequalities on the quality of life pre and postoperative at 3 months after surgery on a french multicenter cohort. * to assess the impact of severity and type of scoliosis on pre- and post-operative quality of life at 3 months and 1 year after surgery on a french multicenter cohort.


Eligibility criteria:
inclusion criteria: * operated by posterior vertebral arthrodesis * opereted in pediatric surgery center * idiopathic scoliosis treated by surgery exclusion criteria: * refusal to participate * people unable to read or speak french (the questionnaire being in french) * non-idiopathic scoliosis

Keywords: inequality remoteness socio economic
a dose finding study of aeb071 assessing psoriasis area and severity index in patients with plaque psoriasis

Conditions: Moderate and Severe Plaque Psoriasis

Summary: this study is designed to provide efficacy and safety data of several doses of aeb071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). the treatment free follow-up period is designed to provide additional safety data and information on disease recurrence after the last dose of the study drug.


Eligibility criteria:
inclusion criteria: * moderate and severe plaque psoriasis diagnosed for at least 12 months (with or without psoriatic arthritis as comorbidity)that requires systemic therapy * severity of disease meeting all of the following three criteria: * pasi score of 10 or greater * total body surface area (bsa) affected by plaque psoriasis of 10% or greater * investigator's global assessment (iga) score of 3 or greater exclusion criteria: * hematological abnormalities * heart rate \ 90 bpm when resting for 5 minutes * family history of long qt syndrome * history of tachyarrhythmia * history of conduction abnormality i.e., pr \> 200 msec, 2nd or 3rd degree av block, complete left or right branch bundle block, pre-excitation syndrome * uncontrolled or unstable angina pectoris; history of myocardial infarction within the previous 12 months * known history of congestive heart failure * history of percutaneous coronary intervention (pci) or cardiac ablation * history of stroke or transient ischemic attack (tia) * implanted cardiac pacemaker or defibrillator * history of malignancy of any organ system * current guttate, generalized erythrodermic, or pustular psoriasis * current drug associated psoriasis other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriasis plaque psoriasis inflammatory skin disease scaly patches aeb071
comparison of two types of ankle braces in the management of ankle pain in hemophilia

Conditions: Arthropathy Due to Bleeding From Hemophilia

Summary: this project proposes to examine the difference in effectiveness of fracture boots and carbon fiber braces in the management of gait abnormalities and pain relief due to ankle pain from arthritis due to ankle bleeds. fracture boots are "walking casts" that you can put on and take off. they prevent the ankle from moving and have a curved sole to mimic normal walking. they can help relieve pain of ankle arthritis from ankle bleeds by stopping ankle motion and absorbing some of the body's own weight while walking. carbon fiber braces use newer technology resulting in lighter and smaller braces. they are designed to assist with helping clear the toe and straighten the knee while walking. gait analysis wearing both the fracture boot and carbon fiber brace will be performed by walking on a mat equipped with pressure sensors and will examine the effect of the fracture boot and the carbon fiber brace on how you walk. these tests will be compared to walking on the mat without either brace. the sensors on the mat will measure different aspects of gait such as step length and foot position. you will be asked questions about how much ankle pain you have using no brace compared to each brace. people with hemophilia a or b and ankle pain from bleeds will be asked to participate. they will be approached during routine clinic visits and will also be contacted by telephone. levels of pain will be measured before, during and after each trial using standardized visual analog and ordinal pain scales. measurements from the gait mat and levels of pain relief will be used to determine effectiveness of each type of support. statisticians will be used to analyze results of the gait mat and pain scale measurements.


Eligibility criteria:
inclusion criteria: * hemophilia a or b, with or without inhibitor, with unilateral or bilateral ankle pain exclusion criteria: * none
cohort of neurovascular diseases treated in the acute phase and followed at lariboisière

Conditions: Ischemic Stroke; Hemorrhagic Stroke

Summary: neurovascular diseases can cause ischaemic or haemorrhagic strokes. while the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. what's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the lariboisière neurovascular intensive care unit (usinv) could provide a particularly rich resource.


Eligibility criteria:
inclusion criteria: 1. adult patients ≥18 years 2. patients admitted to the neurovascular intensive care unit with acute cerebrovascular disease or patients managed for acute cerebrovascular pathology with or without stroke by the lariboisière neurology team. 3. no opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative. exclusion criteria: 1. patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship 2. patient suffering from a rare neurovascular disease and being followed at the "centre de référence des maladies vasculaires rares du cerveau et de l'oeil" (cervco)
the effect of pseudoephedrine on rhinitis and sleep

Conditions: Rhinitis; Sleep

Summary: the hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a decongestant, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round perennial allergic rhinitis (par). this decrease in sleep fragmentation will reduce daytime somnolence and fatigue.

the hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a decongestant, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round perennial allergic rhinitis (par). this decrease in sleep fragmentation will reduce daytime somnolence and fatigue. we studied patients treated with placebo compared to fda approved dose of pseudoephedrine and assessed sleep, qol and daytime sleepiness.

Eligibility criteria:
inclusion criteria: 1. age 18 to 65. 2. history of allergic rhinitis. 3. the ability to be placed on placebo without significant compromise in the quality of life. 4. general good health. 5. ability to comply with the protocol and sign an informed consent. 6. have daytime sleepiness by history. 7. have poor sleep by history. 8. have fatigue by history. 9. have a skin test or rast test to a perennial allergen (indoor mold, dog, cat, mite) with correlating symptoms. exclusion criteria: 1. age fewer than 18 or over 65 years. 2. a history of sleep apnea. 3. atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma. 4. non-allergic rhinitis. 5. hypertension 6. diabetes mellitus 7. inability to tolerate pseudoephedrine 8. significant other diseases as determined by the investigator. 9. use of a research medication within 30 days. 10. use of a nasal steroid or topical antihistamine or decongestant within 30 days. 11. use of beta-blockers, antidepressants, oral decongestants, oral steroids, or h2-blockers. 12. excessive use of alcohol or drug abuse. 13. inability to stop medication use during run-in period. 14. use of an oral antihistamine within 1 week of enrollment. 15. failed to have benefit when pseudoephedrine was used for rhinitis or asthma in the past

Keywords: sleep, pseudoephedrine